Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Zachery D. Schultz"'
Autor:
Jennifer L. Schehr, Nan Sethakorn, Zachery D. Schultz, Camila I. Hernandez, Rory M. Bade, Diego Eyzaguirre, Anupama Singh, David J. Niles, Leslie Henderson, Jay W. Warrick, Scott M. Berry, Kaitlin E. Sundling, David J. Beebe, Ticiana A. Leal, Joshua M. Lang
Publikováno v:
Biomarker Research, Vol 10, Iss 1, Pp 1-13 (2022)
Abstract Introduction PD-L1 expression in non-small cell lung cancer (NSCLC) predicts response to immune checkpoint blockade, however is an imperfect biomarker given tumor heterogeneity, and the antigen presentation pathway requiring other components
Externí odkaz:
https://doaj.org/article/b9045af0a9af4371a592c3d1c272ffac
Autor:
Shuang G. Zhao, Jamie M. Sperger, Jennifer L. Schehr, Rana R. McKay, Hamid Emamekhoo, Anupama Singh, Zachery D. Schultz, Rory M. Bade, Charlotte N. Stahlfeld, Cole S. Gilsdorf, Camila I. Hernandez, Serena K. Wolfe, Richel D. Mayberry, Hannah M. Krause, Matt Bootsma, Kyle T. Helzer, Nicholas Rydzewski, Hamza Bakhtiar, Yue Shi, Grace Blitzer, Christos E. Kyriakopoulos, David Kosoff, Xiao X. Wei, John Floberg, Nan Sethakorn, Marina Sharifi, Paul M. Harari, Wei Huang, Himisha Beltran, Toni K. Choueiri, Howard I. Scher, Dana E. Rathkopf, Susan Halabi, Andrew J. Armstrong, David J. Beebe, Menggang Yu, Kaitlin E. Sundling, Mary-Ellen Taplin, Joshua M. Lang
Publikováno v:
The Journal of Clinical Investigation, Vol 132, Iss 21 (2022)
Background Neuroendocrine prostate cancer (NEPC) is an aggressive subtype, the presence of which changes the prognosis and management of metastatic prostate cancer.Methods We performed analytical validation of a Circulating Tumor Cell (CTC) multiplex
Externí odkaz:
https://doaj.org/article/ec5e2f5145314e94b0c25808c0d5eee0
Autor:
Matthew Bootsma, Rana R. McKay, Hamid Emamekhoo, Rory M. Bade, Jennifer L. Schehr, Matthew C. Mannino, Anupama Singh, Serena K. Wolfe, Zachery D. Schultz, Jamie Sperger, Wanling Xie, Sabina Signoretti, Christos E. Kyriakopoulos, David Kosoff, Edwin J. Abel, Kyle T. Helzer, Nicholas Rydzewski, Hamza Bakhtiar, Yue Shi, Grace Blitzer, Michael Bassetti, John Floberg, Menggang Yu, Nan Sethakorn, Marina Sharifi, Paul M. Harari, Toni K. Choueiri, Joshua M. Lang, Shuang G. Zhao
Publikováno v:
Journal of Clinical Oncology. 40:3633-3641
PURPOSE Liquid biopsies in metastatic renal cell carcinoma (mRCC) provide a unique approach to understand the molecular basis of treatment response and resistance. This is particularly important in the context of immunotherapies, which target key imm
Autor:
Jennifer L Schehr, Zachery D Schultz, Jay W Warrick, David J Guckenberger, Hannah M Pezzi, Jamie M Sperger, Erika Heninger, Anwaar Saeed, Ticiana Leal, Kara Mattox, Anne M Traynor, Toby C Campbell, Scott M Berry, David J Beebe, Joshua M Lang
Publikováno v:
PLoS ONE, Vol 11, Iss 7, p e0159397 (2016)
Expression of programmed-death ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC) is typically evaluated through invasive biopsies; however, recent advances in the identification of circulating tumor cells (CTCs) may be a less invasive method to
Externí odkaz:
https://doaj.org/article/8f6661b01ec84d04955efc3f9136e5d9
Autor:
Jennifer L. Schehr, Nan Sethakorn, Zachery D. Schultz, Camila I. Hernandez, Rory M. Bade, Diego Eyzaguirre, Anupama Singh, David J. Niles, Leslie Henderson, Jay W. Warrick, Scott M. Berry, Kaitlin E. Sundling, David J. Beebe, Ticiana A. Leal, Joshua M. Lang
Publikováno v:
Biomarker research. 10(1)
Introduction PD-L1 expression in non-small cell lung cancer (NSCLC) predicts response to immune checkpoint blockade, however is an imperfect biomarker given tumor heterogeneity, and the antigen presentation pathway requiring other components includin
Autor:
Jennifer L. Schehr, Sacha Horn, Anupama Singh, Charlotte N. Stahlfeld, David J. Beebe, Hannah M. Pezzi, Jacob Rothbauer, Zachery D. Schultz, Joshua M. Lang, Scott M. Berry, David J. Guckenberger, Rory M. Bade, Jamie M. Sperger
Publikováno v:
Lab on a Chip. 18:3446-3458
Rare cell populations provide a patient-centric tool to monitor disease treatment, response, and resistance. However, understanding rare cells is a complex problem, which requires cell isolation/purification and downstream molecular interrogation - p
Autor:
Ticiana Leal, Zachary S. Morris, Nan Sethakorn, Kristina A. Matkowskyj, Michael F. Bassetti, Toby C. Campbell, Brett A. Morris, Anne M. Traynor, Joshua Michael Lang, Narjust Duma, Andrew M. Baschnagel, Zachery D. Schultz, Jennifer L. Schehr, Jens C. Eickhoff
Publikováno v:
Journal of Clinical Oncology. 39:e21212-e21212
e21212 Background: Combining local ablative and systemic therapies in patients with oligometastatic NSCLC leads to improved overall survival (OS) and progression-free survival (PFS). The potential immunostimulatory effects of ablating all visible dis
Autor:
Joshua M. Lang, David J. Beebe, Jaime M. Sperger, Zachery D. Schultz, Charlotte N. Stahlfeld, Molly M. Morgan, Anupama Singh, Rory M. Bade, Jennifer L. Schehr, Madalyn S. Gill, Jay W. Warrick, Hannah M. Pezzi
Publikováno v:
Clinical Cancer Research. 26:B40-B40
The efficacy of androgen receptor (AR) signaling inhibitors (ARSIs) in prostate cancer is limited by both de novo and acquired resistance. Two well-described mechanisms of resistance to ARSIs are the development of constitutively activated AR splice
Autor:
Ticiana A. Leal, Zachery D. Schultz, Jennifer L. Schehr, Camila I. Hernandez, Jay W. Warrick, Matthew C. Mannino, Joshua M. Lang, David J. Beebe
Publikováno v:
Clinical Cancer Research. 26:PR10-PR10
Only a subset of patients with non-small cell lung cancer (NSCLC) respond to PD-L1 targeted therapy, even after solid tumor biopsy screening for PD-L1 expression. Downregulation of HLA I may contribute to this high prevalence of resistance, warrantin
Autor:
Anwaar Saeed, Hannah M. Pezzi, David J. Beebe, Scott M. Berry, Jamie M. Sperger, Anne M. Traynor, Erika Heninger, Jennifer L. Schehr, Toby C. Campbell, Zachery D. Schultz, Joshua M. Lang, Jay W. Warrick, David J. Guckenberger, Ticiana Leal, Kara Mattox
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 7, p e0159397 (2016)
PLoS ONE, Vol 11, Iss 7, p e0159397 (2016)
Background Expression of programmed-death ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC) is typically evaluated through invasive biopsies; however, recent advances in the identification of circulating tumor cells (CTCs) may be a less invasive